Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efavirenz/emtricitabine/tenofovir disoproxil fumarate

Drug Profile

Efavirenz/emtricitabine/tenofovir disoproxil fumarate

Alternative Names: ATR; Atripla

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Gilead Sciences; Merck & Co
  • Class Antiretrovirals; Benzoxazines; Nucleotides; Phosphonic acids; Purines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2017 Gilead terminates its collaboration with Bristol-Myers Squibb for Efavirenz/emtricitabine/tenofovir disoproxil fumarate in USA and Canada
  • 27 Feb 2017 Gilead Sciences has patent protection for Efavirenz/emtricitabine/tenofovir disoproxil fumarate in USA and European Union (Gilead Sciences 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top